Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma
NCT03985722Phase 1Unknown
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Sep 2018
- Primary completion
- Feb 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaratumab in soft tissue sarcoma (STS), sponsored by Spanish Group for Research on Sarcoma. Primary endpoint: Maximum Tolerated Dose at 18 months. Status: unknown.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03985722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985722.